TheCapTable
Subscribe

Stories

About Us

Home

Stories

Explore

Sign In

Stories

About Us

HealthTech

Pharma distributors tighten the screws on e-pharmacies after PharmEasy debacle

thumbnail
August 01, 2023  |  7 Min Read
With PharmEasy set for a massive drop in valuation, pharma distributors are a wary lot. Having shared an uneasy relationship with e-pharmacies for the last five years, they’re changing the terms of their agreements with e-pharmacies to protect themselves from any further implosions in the space.

Key Takeaways

  • With PharmEasy’s valuation set to plummet from its pandemic high of $5.5 billion, pharma distributors are reconsidering their already uneasy equation with e-pharmacies
  • Some are reworking agreements with e-pharmacy clients, shortening credit periods and blacklisting those that ask for payment deadline extensions
  • E-pharmacies, many of which set up their own supply chains to rival traditional distributors, are realising that this is not the relationship of equals
  • This could make things harder for e-pharmacies, which are already struggling to chart a path to profitability

Being India's biggest e-pharmacy hasn’t been enough to keep the wolf from PharmEasy’s door.

Mired in losses—PharmEasy’s parent company recorded a loss of Rs 3,992 crore in the year ended March 2022—and burdened with debt, the company is currently attempting to orchestrate a life-saving rights issue to raise capital. This, however, would likely still see the valuation of Mumbai-headquartered PharmEasy drop from $5.5 billion during its last fundraise in 2021 to just north of $700 million, according to reports.

PharmEasy’s unravelling has cast a pall over the wider e-pharmacy space, with investors and industry experts wondering if this is just the start of a wider reckoning in the sector. Tata 1mg, PharmEasy’s biggest rival, also reported a loss of Rs 526 crore in the year ended March 2022.

Stakeholders in the pharma ecosystem are looking on with concern. Pharma distributors, spooked by the PharmEasy debacle, are reconsidering their already uneasy equation with e–pharmacies.

This is a premium article and available only to subscribers.

Already a subscriber? Sign In

What's your right fit?

Be the smartest person in the room. Choose the plan that works for you and join our exclusive subscriber community.

premium_articles

Premium Articles

4 articles every week

archives

Archives

>3 years of archives

archives

Org. Chart

1 every week

newsletter

Newsletter

4 every week

gifting_credits

Gifting Credits

5 premium articles every month

session

Session

3 screens concurrently

1,999 / Year

3,999

Subscribe Now

Have a coupon code?

Join our community of 100,000+ top executives, VCs, entrepreneurs, and brightest student minds

company1
company2
company3
company4
company5
company6
company7
company8
company9
SPJIMR Logo
company1
company2
company3
company4
company5
company6
company7
company8
company9
SPJIMR Logo
Trusted by the best
Headshot of Karthik Reddy from Blume Ventures
Karthik Reddy

Blume Ventures

quote

The CapTable brings a refreshing set of insights for us at the Blume team, highlighting stories that bring together the underlying business and founders with that of investors' journeys with these startups. It's an important perspective that very few bring to startup ecosystem enthusiasts.

Latest Articles

subscribe_graffiti

Convinced that The Captable stories
and insights will give you the edge?

Subscribe Now

If you want to see more, Sign Up for access to our Crux newsletter and several free articles

Sign Up Now